导师简介
姓名：张晓东 性别：男 政治面貌：群众 学历：研究生学位： 医学博士 职称：主任医师
博、硕导师：博导 本岗位工作年数：32年
研究方向：慢性肾脏病防治
荣誉称号：
学术任职：目前担任《中国中西医结合肾病杂志》编委；山西医学会肾病分会副主任委员；中华老年医学肾病学组委员；中国医师协会中西医结合分会全国委员；山西医师协会肾病分会副主任委员；
近五年承担科研课题情况：
例如：中央引导地方科技发展资金项目（自由探索类基础研究） 项目名称：脊髓损伤后膀胱功能障碍的代谢组学研究，项目编号: YDZJSX2022A065
1.山西省基础研究计划自然科学研究面上项目（自由探索类）：项目名称：益肾胶囊上调SIRT6/HIF-1a信号通路改善糖尿病肾病肾小管上皮细胞焦亡的机制，项目编号: 202403021211152；经费7万；年限：2024年7月-2027年7月
2.山西省重点研发项目（国际科技合作方面）：项目名称：益肾汤经结肠透析调控SIRT1/NF-Kb信号通路干预CRF肠粘膜屏障损伤的研究：项目编号: 201803D421063；经费10万，年限：2019年1月至2021年12月
代表性论著及近五年的代表性论文（限10项以内）：
例如：主编.神经源性膀胱[M].北京：人民卫生出版社，2009.1 ISBN 978-7-117-11004-4/R·11005
1.Liang N, Ma X, Cao Y,Liu T, Fang JA,Zhang X. Mendelian Randomization Studies: Opening a New Window in the Study of Metabolic Diseases and Chronic Kidney Disease.Endocr Metab Immune Disord Drug Targets. 2025;25(6):442-457.
2.Kong K, Qiao X,Liu T, Wang X, Li R, Fang J,Zhang X.Identification of Novel Hub Genes Associated with Inflammation and Autophagy in Astragaloside Membranaceus ameliorates Lupus Nephritis by Bioinformatics Analysis and Molecular Dynamics Simulation.Comb Chem High Throughput Screen. 2025;28(2):306-318.
3.Liu T, Cao Y, Liang N, Ma X, Fang JA,Zhang X. Investigating the causal association between gut microbiota and type 2 diabetes: a meta-analysis and Mendelian randomization.Front Public Health. 2024 Jun 19;12:1342313.
4.Cao Y, Liang N, Kong K, Qiao X,Liu T, Fang JA,Zhang X. CD163 as a Potential Biomarker-associated Immune Inflammation in Diabetes Mellitus: A Systematic Review and Bioinformatics Analysis.Endocr Metab Immune Disord Drug Targets. 2024;24(2):208-219.
5.Qiao X, Kong K,Liu T, Jia Y, Fang J,Zhang X. Gut-Skin Axis: Unravelling the Link Between Gut Microbiome and Chronic Kidney Disease-Related Skin Lesions.Endocr Metab Immune Disord Drug Targets. 2024;24(1):39-49.
6.Cao Y, Liang N,Liu T, Fang J,Zhang X. Effect of SGLT2 Inhibitors and Metformin on Inflammatory and Prognostic Biomarkers in Type 2 Diabetes Patients.Endocr Metab Immune Disord Drug Targets. 2023;23(4):530-547.
7.Wang X, Li R,Liu T, Jia Y, Gao X,Zhang X. CD163 in Macrophages: A Potential Biomarker for Predicting the Progression of Diabetic Nephropathy based on Bioinformatics Analysis.Endocr Metab Immune Disord Drug Targets. 2023;23(3):294-303.
8.Liu T, Li R, Wang X, Gao X,Zhang X. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.Med Clin (Barc). 2022 Jul 22;159(2):65-72.
9.Liu T, Wang X, Li R, Zhang ZY, Fang J,Zhang X. Effects of Probiotic Preparations on Inflammatory Cytokines in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.Curr Pharm Biotechnol. 2021;22(10):1338-1349.
10.Liu Y, Liu W, Zhang Z, Hu Y,Zhang X, Sun Y, Lei Q, Sun D,Liu T, Fan Y, Li H, Ding W, Fang J. Yishen capsule promotes podocyte autophagy through regulating SIRT1/NF-κB signaling pathway to improve diabetic nephropathy.Ren Fail. 2021 Dec;43(1):128-140.
